Claims for Patent: 8,993,640

Summary for Patent: 8,993,640

Title:	2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Abstract:	The present invention relates generally to the compound:
Inventor(s):	Anderson Eric, Liu Xiaofeng, Decker Andrea
Assignee:	Reata Pharmaceuticals, Inc.
Application Number:	US13869833
Patent Claims:	3. The polymorphic form of claim 2 , wherein the X-ray powder diffraction pattern (CuKα) further comprises a shoulder peak at about 8° 2θ.4. The polymorphic form of claim 2 , wherein the X-ray powder diffraction pattern (CuKα) is as shown in .5. The polymorphic form of claim 2 , further having a Tfrom about 150° C. to about 155° C.6. The polymorphic form of claim 2 , further having a differential scanning calorimetry (DSC) curve comprising an endotherm centered from about 150° C. to about 155° C.7. The polymorphic form of claim 2 , having a differential scanning calorimetry (DSC) curve as shown in .9. The polymorphic form of claim 8 , wherein the X-ray powder diffraction pattern (CuKα) is as shown in claim 8 , top pattern.11. The polymorphic form of claim 10 , wherein the X-ray powder diffraction pattern (CuKα) is as shown in claim 10 , second pattern from top.13. The polymorphic form of claim 12 , wherein the X-ray powder diffraction pattern (CuKα) is as shown in claim 12 , second pattern from bottom.14. The polymorphic form of claim 12 , further having a Tof about 196° C.15. The polymorphic form of claim 12 , further having a differential scanning calorimetry (DSC) curve comprising an endotherm centered at about 196° C.16. The polymorphic form of claim 12 , having a differential scanning calorimetry (DSC) curve as shown in .18. The polymorphic form of claim 17 , wherein the X-ray powder diffraction pattern (CuKα) is as shown in claim 17 , bottom pattern.19. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'an active ingredient consisting of a compound of , and'}a pharmaceutically acceptable carrier.20. A method of treating a condition associated with inflammation or oxidative stress claim 19 , selected from the group consisting of prostate cancer claim 19 , dermatitis claim 19 , sepsis claim 19 , pulmonary inflammation claim 19 , pulmonary fibrosis claim 19 , COPD claim 19 , asthma claim 19 , mucositis claim 19 , and ocular inflammation claim 19 , in a patient in need thereof claim 19 , comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of .21. The method of claim 20 , wherein the dermatitis is radiation-induced dermatitis.22. The method of claim 20 , wherein the mucositis is mucositis resulting from radiation therapy or chemotherapy.23. A method of reducing the duration and/or severity of radiation-induced oral mucositis or radiation-induced dermatitis in a patient in need of acute radiation treatment comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of prior to and/or after said acute radiation treatment.